Hydrogen-rich water inhibits glucose and α,β -dicarbonyl compound-induced reactive oxygen species production in the SHR.Cg-Leprcp/NDmcr rat kidney.
Masanori Katakura, Michio Hashimoto, Yoko Tanabe, Osamu Shido · Medical gas research · 2012
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In Wistar rats, sHR.Cg-Leprcp/NDmcr rats treated with HRW showed a 34% decrease in ROS production. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in Wistar rats. SHR.Cg-Leprcp/NDmcr rats treated with HRW showed a 34% decrease in ROS production.
What the Researchers Studied
The researchers studied Wistar rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 16 weeks. SHR.Cg-Leprcp/NDmcr rats treated with HRW showed a 34% decrease in ROS production. The authors concluded that these results indicate that HRW inhibits the production of α,β-dicarbonyl compounds and ROS in the kidneys of SHR.Cg-Leprcp/NDmcr rats.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was Wistar rats. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The reported treatment duration was 16 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.